CEVEC is a leading provider of high-performance cell technology for the manufacturing of advanced bio-therapeutics from R&D to manufacturing scale. The company’s product portfolio comprises platform technologies for gene therapy viral vectors, vaccines and complex recombinant proteins. With the ELEVECTA® Technology, CEVEC offers a unique solution for large-scale production of AAV vectors using helper virus-free producer cell lines with all necessary components stably integrated into the cell. The technology is based on suspension cells and does not require any expensive transfection reagents nor cGMP plasmids. CEVEC’s CAP® Ad Technology is the ideal production platform for RCA-free adenoviral vectors. Based on human suspension cells, it allows for a robust manufacturing process, easy scale-up from research grade to industrial volumes and thus opens the way for various applications, from gene therapy to vaccine production. With the CAP-Go® Technology CEVEC provides a solution to the increasing need for recombinant production of complex and highly glycosylated protein molecules, including laminins, coagulation factors and plasma proteins.
View Top Employees from CEVEC Pharmaceuticals GmbHWebsite | http://www.cevec.com |
Revenue | $6 million |
Employees | 37 (34 on RocketReach) |
Founded | 2003 |
Address | 60-62 Gottfried-hagen-str., Koeln, North Rhine-Westphalia 51105, DE |
Phone | +49 221 46020801 |
Fax | +49 221 46020801 |
Technologies |
JavaScript,
HTML,
PHP
+7 more
(view full list)
|
Industry | Biotechnology, Business Services General, Biopharma, Business Services, Health Care, Science and Engineering |
Web Rank | 12 Million |
Keywords | Cap Gt Platform, Cevec Pharmaceuticals Gmbh, Cevec, Challenges In Viral Therapy Production |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 541 Companies, NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 54 Companies, NAICS Code 541714 Companies |
Looking for a particular CEVEC Pharmaceuticals GmbH employee's phone or email?
The CEVEC Pharmaceuticals GmbH annual revenue was $6 million in 2024.
Frank Ubags is the CEO of CEVEC Pharmaceuticals GmbH.
34 people are employed at CEVEC Pharmaceuticals GmbH.
CEVEC Pharmaceuticals GmbH is based in Koeln, North Rhine-Westphalia.
The NAICS codes for CEVEC Pharmaceuticals GmbH are [541, 5417, 54171, 54, 541714].
The SIC codes for CEVEC Pharmaceuticals GmbH are [873, 87].